UroGen Pharma Ltd. (URGN) financial statements and ratios from SEC XBRL: revenue $0.2B (TTM), net margin -139.8%, revenue growth 199.2% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $109.79M |
| Revenue (TTM) | $0.2B |
| Net Margin | -139.8% |
| Operating Margin (TTM) | -35.3% |
| Net Debt / EBITDA | -1.7 |
| Revenue Growth (YoY) | 199.2% |
| EPS Growth (YoY) | -73.3% |
| FCF Growth (YoY) | -17.3% |
| Price / Sales | 12.09 |
| FCF Yield | -7.0% |
| Altman Z-Score | -2.90 (distress) |
| Piotroski F-Score | 1/9 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
URGN overview · URGN earnings · URGN KPIs · URGN documents · URGN ownership · URGN peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.